Other studies have found that sorafenib triggers a switch from HIF-1α-dependent to HIF-2α-dependent pathways, promoting the expression of VEGF and cyclin D1, thus enhancing sorafenib resistance and tumor growth (13, 14). This evidence concerns the gene EPAS1 and neoplasm.